BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34609744)

  • 1. Technical Note: Break-even dose level for hypofractionated treatment schedules.
    Böhlen TT; Germond JF; Bourhis J; Vozenin MC; Bailat C; Bochud F; Moeckli R
    Med Phys; 2021 Nov; 48(11):7534-7540. PubMed ID: 34609744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
    Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
    Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of normal tissue-to-tumor α/β ratio when evaluating isodoses of isoeffective radiation therapy treatment plans.
    Gay HA; Jin JY; Chang AJ; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e81-7. PubMed ID: 23141886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
    Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
    Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor.
    Otsuka S; Shibamoto Y; Iwata H; Murata R; Sugie C; Ito M; Ogino H
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1538-43. PubMed ID: 22115556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation.
    Astrahan M
    Med Phys; 2008 Sep; 35(9):4161-72. PubMed ID: 18841869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of the linear-quadratic model to single and fractionated radiotherapy schedules: an experimental study.
    Miyakawa A; Shibamoto Y; Otsuka S; Iwata H
    J Radiat Res; 2014 May; 55(3):451-4. PubMed ID: 24351457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.
    Chan MKH; Chiang CL
    Strahlenther Onkol; 2021 Jul; 197(7):622-632. PubMed ID: 33245378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning of head and neck cancers.
    Quashie EE; Li XA; Prior P; Awan M; Schultz C; Tai A
    Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37903437
    [No Abstract]   [Full Text] [Related]  

  • 11. Ten-Fraction Stereotactic Radiosurgery With Different Gross Tumor Doses and Inhomogeneities for Brain Metastasis of >10 cc: Treatment Responses Suggesting Suitable Biological Effective Dose Formula for Single and 10 Fractions.
    Ohtakara K; Nakabayashi K; Suzuki K
    Cureus; 2023 Feb; 15(2):e34636. PubMed ID: 36895545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling late effects in hypofractionated stereotactic radiotherapy.
    Hoban PW; Jones LC; Clark BG
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):199-210. PubMed ID: 9989527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalized Multi-Hit Model of Radiation-Induced Cell Survival with a Closed-Form Solution: An Alternative Method for Determining Isoeffect Doses in Practical Radiotherapy.
    Zhao L; Chen X; Tian J; Shang Y; Mi D; Sun Y
    Radiat Res; 2020 Apr; 193(4):359-371. PubMed ID: 32031917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction.
    Brenner DJ
    Semin Radiat Oncol; 2008 Oct; 18(4):234-9. PubMed ID: 18725109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fractionation schedules in the large heterogeneity limit.
    Guerrero M
    Med Phys; 2009 Apr; 36(4):1384-8. PubMed ID: 19472645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
    Pop LA; Millar WT; Visser AG; van der Kogel AJ
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters.
    Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Bengua G; Onimaru R; de Josien Bois A; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1596-603. PubMed ID: 20231066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
    Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
    Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A challenge to traditional radiation oncology.
    Fowler JF; Tomé WA; Fenwick JD; Mehta MP
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1241-56. PubMed ID: 15519797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.